On-mine cost guidance rose to $1,700-$1,900 per ounce sold; group capex fell to $94.3 million. Normalized production is ...

The average price was $158.2702 per share; the company bought the shares through Goldman Sachs International on the London ...

The planned facility is envisioned to produce hundreds of fusion machines annually; TRIDEC will coordinate site evaluation, ...

The trial also reported complete symptom resolution at 11.95 hours, no safety signals, and regulatory applications under ...

Secured capacity totals about 273.5MW, or about 78% of a target of up to 350MW by Q1 2028; full campus delivery is targeted ...

CMS rated Clover’s HMO plan 4.5 stars; with 20 measures included, its PPO rating would be 4.5. Clover’s HEDIS score was 4.82 ...

Canadian clients will gain access to insurance placement, specialty risk consulting and portfolio analysis, helping investors assess acquisition and operating risks earlier.

In the 712-patient ATOMIC trial, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy, versus 76% with chemotherapy alone.

In ATOMIC, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy versus 76% with chemotherapy alone; Roche is pursuing European filings.

Recent: Retension Pharmaceuticals Announces Pricing of Initial Public Offering . Track all RTSN press releases, SEC filings, and market updates. Latest RTSN news updated today, October 8.

Underwriters may buy up to 300,000 more shares under a 30-day option. Closing is expected Oct. 19; proceeds are intended for a life-sciences loan commitment.

The five-day program runs Oct. 7-11; remaining care packages will go to people in need, and NBA legends and coaches will ...